QUAGLINO, Pietro

QUAGLINO, Pietro  

SCIENZE MEDICHE  

Mostra records
Risultati 1 - 20 di 184 (tempo di esecuzione: 0.015 secondi).
Titolo Data di pubblicazione Autore(i) File
1975-2011 Overall Survival, Disease Free Survival and Survival after Recurrence across gender in melanoma patients: what has changed? 2012 Simone Ribero; Pietro Quaglino; Martina Sanlorenzo; Simona Osella-Abate; Federica Marenco; Tiziana Nardò; Giuseppe Macripò; Maria Teresa Fierro; Maria Grazia Bernengo
262 Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study 2017 Kim, Y.H.; Whittaker, S.; Horwitz, S.M.; Duvic, M.; Dummer, R.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.; Wolter, P.; Wang, Y.; Palanca-Wessels, M.; Zagadailov, E.; Trepicchio, W.L.; Lin, H.; Little, M.; Prince, H.
A multicenter, d ouble blind, randomized, placebo-controlled, phase II trial to evaluate resminostat for maintenance treatment of patients with advanced stage (stage IIB–IVB) mycosis fungoides (MF) or Sézary syndrome (SS) that have achieved disease control with systemic therapy: the RESMAIN study 2019 Stadler, R.; Scarisbrick, J.; Knobler, R.; Quaglino, P.; Borgmann, M.; Orlovius, M.; Reimann, P.; Danhauser-Riedl, S.
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. 2011 Simona Rolla; Valentina Bardina; Marinella Clerico; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli
Abstract 5603: Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies 2017 Sanlorenzo, Martina; Vujic, Igor; Floris, Arianna; Novelli, Mauro; Donini, Chiara; Gammaitoni, Loretta; Giraudo, Lidia; Macagno, Marco; Quaglino, Pietro; Fierro, Maria Teresa; Giordano, Silvia; Carnevale-Schianca, Fabrizio; Aglietta, Massimo; Sangiolo, Dario
Activity and safety of bexarotene as maienance therapy in CTCL patients with stable disease or remission after systemic treatments: a prospective multicenter trial from the GILC 2011 Quaglino P
Activity and safety of bexarotene as maintainance therapy in advanced/aggressive CTCL patients with stable disease or remission after systemic treatment: an observational multicenter trial from the GILC 2007 Pietro Quaglino; Maria Grazia Bernengo
Activity and safety of Bexarotene as maintenance therapy in CTCL patients (Mycosis Fungoides stage IIB-IV, Sezary Syndrome, peripheral T-cell lymphoma) with stable disease or remission after systemic treatments: A prospective multicenter trauil from the Italian Group of Cutaneous Lymphoma (GILC) 2011 Quaglino P;Pimpinelli N; Alaibac M; Quintini G; Bernengo MG
Alemtuzumab - low dose therapy schedule effective for CTCL 2011 Quaglino Pietro
Alemtuzumab for the treatment of Sézary sindrome: clinical and immunological findings in 10 patients. 2006 Bernengo MG; Quaglino P; Comessatti A; Ortoncelli M; Novelli M; Fierro MT.
Alemtuzumab nel trattamento dei linfomi cutanei a cellule T in fase avanzata: studio pilota “dose finding”. 2004 Savoia P; Fierro MT; Quaglino P; Peroni A; Comessatti A; Bernengo MG.
Alterazioni funzionali e fenotipiche dei polimorfonucleati nei pazienti affetti da dermatite atopica 2011 Banche G; Allizond V; Novelli M; Fierro MT; Mandras N; Murabito P; Quaglino P; Scalas D; Merlino C; Roana J; Tullio V; Bernengo MG; Cuffini AM
Alterazioni funzionali e fenotipiche dei polimorfonucleati nella sindrome di sezary 2009 G. Banche; M.T. Fierro; M. Novelli; V. Allizond; A. Comessatti; P. Quaglino; D. Scalas; C. Merlino; M.G. Bernengo; A Cuffini
An international multi-institutional study for the evaluation of folliculotropic mycosis fungoides: results of the Consensus Histopathologic Review 2019 Gru, Alejandro A.; Mitteldorf, Christina; Pulitzer, Melissa; Hodak, Emmilia; Scarisbrick, Julia; Zic, John; Kempf, Werner; Guenova, Emmanuela; Haun, Paul; Torres-Cabala, Carlos; Robson, Alistair; Querfeld, Christiane; Junkins-Hopkins, Jacqueline; Cozzio, Antonio; Papadavid, Lia; Quaglino, Pietro; Beltraminelli, Helmut; Knobler, Robert; Stadler, Rudi; Geskin, Larisa; Bagot, Martine; Subtil, Antonio; Sanches, Jose A.; Guitart, Joan; Rooke, Bethanie; Duvic, Madeleine; Ortiz, Pablo; Kim, Youn; Battistella, Maxime
Associazione di ciclofosfamide, vincristina e prednisone (COP) nel trattamento dei linfomi cutanei: 20 anni di follow-up. 1996 Fierro MT; Verrone A; Savoia P; Quaglino P; Doveil GC; Bernengo MG
Associazione di etoposide, idarubicina, ciclofosfamide, vincristina, prednisone e bleomicina (VICOP-B) nel trattamento dei linfomi cutanei 1995 Doveil GC; Fierro MT; Appino A; Quaglino P; Savoia P
Autoantibody profile in 619 italian patients with cutaneous lupus erythematosus 2018 Verdelli, A; Coi, A; Marzano, A; Antiga, E; Cozzani, E; Quaglino, P; La Placa, M; Benucci, M; De Simone, C; Papini, M; Parodi, A; Bianchi, F; Caproni, M
Biological prognostic factors in advanced metastatic melanoma patients treated with chemoimmunotheraphy. 1997 Fierro MT; Quaglino P; Lisa F; Savoia P; Bernengo MG
Bullous pemphigoid is characterised by a reduction of skin-homing/circulating FOXP3+ Tregs and by a down-regulation of the IL-10 pathway 2012 Quaglino P; Antiga E; Novelli M; Nardò T; Fava P; Ponti R; Osella-Abate S; Caproni M; Fabbri P; Bernengo MG
CD26 (DPP-IV)- A useful marker in Sezary sindrome 1994 Novelli M; Fierro MT; Quaglino P; Lisa F; Doveil GC; Bernengo MG